目的探讨高危型人乳头瘤病毒(HR-HPV)DNA聚合酶链反应(PCR)联合液基薄层细胞学检查(TCT)对宫颈癌前病变筛查的应用与诊断价值。方法对540例TCT结果为非典型鳞状上皮细胞(ASCUS)及以上的患者进行HR-HPV DNA PCR检测,并对检测结果进行分析。结果 TCT阳性合并HPV阳性患者共259例,其中ASCUS、低度鳞状上皮内病变(LSIL)、高度鳞状上皮内病变(HSIL)、鳞状细胞癌(SCC)的例数(阳性率)分别为155例(59.8%)、81例(31.3%)、15例(5.8%)、8例(3.1%);259例患者中ASCUS、LSIL、HSIL、SCC合并HR-HPV的阳性例数(阳性率)分别为28例(18.1%)、20例(24.7%)、10例(66.7%)、8例(100.0%)。HR-HPV和TCT单独检测的敏感性与两者联合检测的敏感性比较,差异具有统计学意义(P<0.05)。HR-HPV、TCT及两者联合检测的阳性预测值分别为25.5%、11.1%、28.2%,阴性预测值分别为68.8%、59.2%、40.8%。结论TCT与HR-HPV DNA PCR检测是筛查宫颈病变的有效方法,能最大程度地...
【英文摘要】
Objective To investigate the application and significance of high risk human papilloma virus(HRHPV) DNA polymerase chain reaction(PCR) combined thinprep cytology test(TCT) determination for the diagnosis of precancerous lesions.Methods A total of 540 patients undergoing TCT determination and showing positive atypical squamous cells of undetermined significance(ASCUS) and above were enrolled and performed HR-HPV DNA PCR,and the results were analyzed.Results The number of TCT positive combined HPV positive wa...